Effect of inhaled bradykinin on indices of airway responsiveness in asthmatic subjects


ABSTRACT: Asthma is characterized by airway hyperresponsiveness, a physiopathological abnormality which may result from the complex interplay between inflammatory cells and proinflammatory mediators. Although kinins are thought to play a role in the pathogenesis of bronchial asthma, it is not known whether bradykinin is able to induce airway hyperresponsiveness.

We have, therefore, investigated the effect of inhaled bradykinin on the changes in airway calibre and in airway hyperresponsiveness to histamine, in a double-blind, randomized study of nine asthmatic subjects. Subjects were studied on two study periods, separated by at least 15 days. On the first day of each study period, subjects inhaled either a single dose of bradykinin or methacholine (placebo) with changes in airway calibre being followed as forced expiratory volume in one second (FEV₁) and as the maximum expiratory flow rate measured at 70% of the vital capacity below total lung capacity (TLC) from a partial forced expiratory manoeuvre (Vp₃₀) at 3, 5, 10, 15, 30, 45 and 60 min, and then every hour for 7 h. Airway responsiveness to histamine, expressed as the provocative concentrations producing a 20% fall in FEV₁ and 40% fall in Vp₃₀ (PC₂₀FEV₁ and PC₄₀Vp₃₀), was measured at 3 and 7 h after inhaling the agonists, then on days 1, 3, 7 and 14.

Inhalation of bradykinin caused rapid bronchoconstriction that peaked at 3–5 min. When compared to placebo, no significant difference in histamine responsiveness was seen after bradykinin in terms of changes in PC₂₀FEV₁ values. However, when airway hyperresponsiveness was measured as PC₄₀Vp₃₀ we were able to show a significant increase in airway reactivity after bradykinin at 3 and 7 h, the geometric mean PC₄₀Vp₃₀ histamine value decreasing 3.2 and 1.9 fold, respectively.

The results of the present study indicate that bradykinin elicits a transient increase of airway hyperresponsiveness in asthmatic subjects, but this was evident only using a sensitive indicator of the changes in airway reactivity, which suggests an effect at the level of the more peripheral airways. These data suggest that bradykinin may play a role in the pathogenesis of airway hyperresponsiveness in human asthma. Eur Respir J., 1994, 7, 1490–1496.

Inflammation is a cardinal feature of asthma [1], the clinical expression of which is airway hyperresponsiveness [2]. Airway hyperresponsiveness, the exaggerated bronchoconstrictor response to various stimuli, may be measured in the laboratory with agents such as histamine and methacholine [3], but may also be expressed as enhanced responsiveness to physical stimuli, such as exercise [4] and inhalation of cold air [5]. Methacholine and histamine exert their effect on airways smooth muscle directly via an interaction with the M₃ and the H₁ receptors, respectively. Although there is a high degree of correlation between the level of hyperresponsiveness determined by the two [3], methacholine is rather different from histamine in not being able to induce vascular responses in the lung. Allergen inhalation results in an increase of airway hyperresponsiveness during natural exposure [6], and in the setting of allergen bronchial challenge, during which most sensitized asthmatic individuals experience both early (EAR) and late (LAR) asthmatic responses [7]. Although the mechanism of this increased airway responsiveness remains unclear, immunoglobulin E (IgE) -mediated production of inflammatory mediators within the bronchial mucosa may contribute to this abnormality [1].

Bradykinin is a naturally occurring vasoactive nonapeptide formed de novo in body fluids and tissues during inflammatory processes. It is generated from circulating kininogens through proteolytic cleavage by a variety of enzymes, the most important of which are tissue and plasma kallikreins [8]. Evidence that kinin generation...
may be increased under conditions which prevail in areas of allergic inflammation in the airways has recently been obtained from studies in asthmatic subjects [9–11]. In addition, bradykinin is reported to possess many pharmacological properties pertinent to the pathogenesis of asthma. These include vasodilatation and increased microvascular leakage [12, 13], bronchoconstriction [14, 15], modulation of mucociliary transport [16, 17], activation of C-fibre nociceptive sensory nerve endings [16, 18], and induction of nonspecific bronchial hyperresponsiveness in animals [19].

Although the wide array of pharmacological activities possessed by bradykinin may be relevant to inflammatory mechanisms in asthma [20], there is uncertainty about the ability of bradykinin to induce bronchial hyperresponsiveness in man and its clinical significance. As part of a series of studies evaluating the role of bradykinin in asthma, we have investigated the changes in airway calibre and in bronchial reactivity to inhaled histamine, after a single bronchoprovocative dose of bradykinin and methacholine, in a double-blind randomized study on asthmatic subjects.

Methods

Subjects

Nine nonsmoking subjects with stable asthma (3 males and 6 females) with a mean (±SEM) age of 26±3 yrs, participated in the study (table 1). Subjects Nos 1, 6 and 8 had moderately hyperresponsive airways (table 1), but, like the remaining six subjects, they had never experienced any severe exacerbation of their asthma. Seven of the subjects studied were atopic, as defined by positive skin prick tests (>2 mm wheal response) to two or more of five common aeroallergens: mixed grass pollen, Dermatophagoides pteronyssinus, Dermatophagoides farinae, dog hair and cat dander (Bencard, Brentford, Middlesex, UK). Their baseline forced expiratory volume in one second (FEV1) was >75% of their predicted values, and none had ever received oral corticosteroids. Inhaled bronchodilators were withheld for at least 12 h prior to each visit, but subjects were allowed to continue their inhaled corticosteroids as usual. Subjects were not studied within 4 weeks of an upper respiratory tract infection and all initial visits to the laboratory were carried out at the same time of day (07.30 h). The study was approved by the Southampton University and Hospitals Ethics Subcommittee and written informed consent was obtained from each subject.

Measurements

Airway calibre was followed both as the FEV1 and as the maximum expiratory flow rate measured at 70% of the vital capacity (VC) below total lung capacity (TLC) from a partial forced expiratory manoeuvre (Vp30). Both measurements were derived from flow-volume curves produced on a rolling seal flow-rate-dependent spiro-meter (Morgan Spiroflow, P.K. Morgan Ltd, Kent, UK) connected to an 85 B desk top computer via an 82940A GP-10 interface (Hewlett Packard, Wokingham, Berkshire, UK). Partial expiratory flow-volume (PEFV) curves were obtained using the technique described by ZAMEL [21]. Briefly, three VC measurements were recorded, and the largest used to define the control VC. The volume from which the PEFV curves were initiated was set at 70% of this control VC and marked-off from TLC. After at least one minute of tidal breathing, during which deep breaths were carefully avoided, subjects were asked to reach, from end-tidal expiration, a volume equal to 70% of their control VC, and to expire forcefully to residual volume (RV). In this way, PEFV curves, standardized for volume and volume history, were obtained and related Vp30 values derived. On reaching RV, subjects inspired to TLC and then expired maximally back to RV, allowing a measurement of FEV1 to be recorded.

The repeatability of the Vp30 measurements was calculated for each triplicate series by working out the individual coefficient of variation (CV) (CV = standard deviation/ arithmetic mean × 100) between repeated measurements for each subject. Vp30 measurements were found to be repeatable with individual CVs ranging from 5 to 13%.

Table 1. – Characteristics of the subjects studied

<table>
<thead>
<tr>
<th>Subject No.</th>
<th>Sex</th>
<th>Age yrs</th>
<th>Baseline FEV1 % pred</th>
<th>PC20 methacholine mg·ml−1</th>
<th>Atopy §</th>
<th>Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>28</td>
<td>75</td>
<td>0.65</td>
<td>+</td>
<td>S</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>31</td>
<td>95</td>
<td>3.40</td>
<td>+</td>
<td>S</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>22</td>
<td>86</td>
<td>2.25</td>
<td>+</td>
<td>S</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>43</td>
<td>77</td>
<td>1.94</td>
<td>-</td>
<td>S</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>24</td>
<td>92</td>
<td>1.42</td>
<td>-</td>
<td>S</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>20</td>
<td>89</td>
<td>0.68</td>
<td>+</td>
<td>S, Bf (1,000 µg)</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>18</td>
<td>104</td>
<td>6.42</td>
<td>+</td>
<td>S</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>21</td>
<td>101</td>
<td>0.40</td>
<td>+</td>
<td>S, Bf (1,000 µg)</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>25</td>
<td>88</td>
<td>2.05</td>
<td>+</td>
<td>S, Bf (500 µg)</td>
</tr>
</tbody>
</table>

Mean ±SEM: 26 ±3 yrs; 90 ±3.3 % pred; 1.54*; 0.40–6.42 mg·ml−1

§: atopic, positive (+) immediate skin test to one or more allergens; *: geometric mean (range); FEV1: forced expiratory volume in one second; PC20: provocative concentration producing a 20% fall in FEV1; F: female; M: male; % pred: percentage of prediction; S: inhaled salbutamol (prn); Bf: inhaled beclomethasone (500–1,000 µg·day−1)
Drug administration and bronchoprovocation

Methacholine, bradykinin and histamine were freshly prepared in 0.9% sodium chloride (saline) on each occasion, to produce a range of doubling concentrations of 0.03–16.00, 0.0039–8.00 and 0.03–8.00 mg·ml⁻¹, respectively. To avoid loss of bradykinin through peptide degradation and adherence to plastic surfaces, the solutions were stored at 4°C until 15 min before inhalation, when the solution was allowed to reach room temperature, and bronchoprovocation was performed within 30 min of preparing the dilutions. On the control study day, a placebo solution consisting of methacholine at a concentration capable of causing a 30% fall in FEV₁ (PC₃₀ FEV₁) in each subject was prepared in 0.9% saline. Pharyngeal irritation can occur during inhalation of bradykinin, so some subjects may have been aware that they were receiving the kinin. To minimize the effect on the principal investigator, methacholine and bradykinin solutions were administered by a second investigator in a separate challenge room.

The aqueous solutions were administered as aerosols generated from a starting volume of 3 ml in a disposable Inspiron Mini-neb nebulizer (C.R. Bard International, Sunderland, UK) driven by compressed air at 8 l·min⁻¹. Under these conditions the nebulizer had an output of 0.48 ml·min⁻¹ and generated an aerosol with a mass median particle diameter of 4.7 µm. Subjects, wearing a nose-clip, inhaled the aerosolized solutions in five breaths from end-tidal volume to TLC via a mouthpiece. Subjects were trained to take 3 s to reach TLC. Before the bronchial challenges, measurements of FEV₁ and Vp₃₀ were made both before and after inhalation of the vehicle solution.

Study design

The study consisted of two phases outside the pollen season.

Phase 1. Evaluation of PC₂₀/PC₃₀ FEV₁ to both methacholine and bradykinin. Subjects attended on two visits to the laboratory, at least 72 h apart, to undertake concentration-response studies with inhaled methacholine and bradykinin. On each occasion, after 15 min of rest, three baseline measurements of FEV₁ were recorded at 3 min intervals. Subjects then inhaled nebulized vehicle diluent solution, and FEV₁ measurements were repeated at 1 and 3 min. Provided that the FEV₁ did not fall by >10% of the baseline value, bronchial provocation testing with one of the two agonist was carried out. After administration of each concentration of agonist, FEV₁ was measured at 1 and 3 min, the higher of the two values being recorded. Increasing concentrations of methacholine or bradykinin were inhaled at 5 min intervals, until FEV₁ had fallen by >30% of the postdiluent baseline value, or until the highest concentrations of agonist had been administered. The percentage decrease in FEV₁ from postdiluent baseline was plotted against the cumulative concentration of agonist administered and that concentration of agonist required to produce a 20 and 30% fall in FEV₁ from the postdiluent baseline value (PC₂₀FEV₁ and PC₃₀FEV₁ respectively) determined by linear interpolation.

Phase 2. Exposure to PC₃₀FEV₁ dose bradykinin or methacholine. This consisted of two study periods separated by at least 14 days (fig. 1), during which subjects inhaled either the PC₃₀FEV₁ bradykinin or matched placebo (i.e. PC₃₀FEV₁ methacholine) in a double-blind, randomized manner, to mimic the bronchoconstrictor effect of bradykinin. On the first day of each study period, subjects attended the laboratory at 07.30 h to undertake a concentration-response study with inhaled histamine, to determine their baseline airways responsiveness. Serial doubling concentrations of histamine (0.03–8.00 mg·ml⁻¹) were administered at 5 min intervals, followed by measurements of Vp₃₀ and FEV₁ at 1 and 3 min

![Fig. 1. – Study design. Phase 2 – exposure to PC₃₀FEV₁ dose bradykinin or methacholine. Bk: bradykinin; Meth: methacholine; PC: bronchoprovocation test with inhaled histamine; PC₃₀FEV₁: provocative concentration producing a 30% fall in forced expiratory volume in one second. *: the order of bradykinin and methacholine exposures was randomized and double-blind.](image-url)
min after inhalation of each dilution. The inhalation and measurements were continued until the FEV₁ had fallen by at least 20% of the postsaline value. Once the FEV₁ had returned to within 5% of the baseline value, (approximately 45–60 min later), the airways response to either placebo (the PC<sub>30</sub>FEV₁ methacholine) or active drug (the PC<sub>30</sub>FEV₁ bradykinin) was assessed, with changes in airway calibre being monitored as FEV₁ and V<sub>p30</sub> at 3, 5, 10, 15, 30, 45 and 60 min, and then at every hour for 7 h. Changes in airways responsiveness, expressed as the PC<sub>30</sub>FEV₁ and the provocative concentration producing a 40% fall in V<sub>p30</sub>(PC<sub>40</sub>V<sub>p30</sub>) histamine, were assessed at 3 and 7 h after inhaling the agonist and then 1, 3, 7 and 14 days after the initial challenge. Thus, one study period comprised 15 days.

**Data analyses**

All figures refer to means (+/- SEM) unless otherwise stated, and the p<0.05 level of significance was accepted. At each study period the magnitude of bradykinin- and methacholine-induced bronchoconstriction was quantified as the maximum percentage fall in V<sub>p30</sub> and FEV₁ achieved within the first 30 min of challenge and compared by Wilcoxon signed rank test.

Concentration response curves to agonists were constructed by plotting the percentage change in FEV₁ and V<sub>p30</sub> from baseline against the cumulative concentration of the agonist on a logarithmic scale. PC<sub>20</sub>FEV₁, PC<sub>30</sub>FEV₁ and PC<sub>40</sub>V<sub>p30</sub> were derived by linear interpolation. To compare the effect of bradykinin and methacholine (placebo) exposure on histamine responsiveness, two-way analysis of variance (ANOVA) followed by the Neuman Keuls procedure was used to analyse the change of the log transformed PC-values observed during bradykinin and control methacholine study periods.

Linear regression analyses were used to determine the relationship between the magnitude of bradykinin-induced bronchoconstriction and the changes in histamine responsiveness. Any relationship between airways responsiveness to bradykinin and that to methacholine, and between maximum falls in FEV₁ and V<sub>p30</sub>, against the corresponding baseline values of histamine PC<sub>20</sub>FEV₁ and PC<sub>40</sub>V<sub>p30</sub> were investigated by least square linear regression. Mann-Whitney U-tests were used to analyse any difference in the airway responses to bradykinin between the moderately hyperresponsive and the mild hyperresponsive subjects and the steroid and nonsteroid users. Similarly, any difference in histamine airway responsiveness after bradykinin exposure between the steroid and nonsteroid users was analysed by Mann-Whitney U-test.

**Results**

**Effect of bradykinin on the airway calibre**

Inhalation of bradykinin caused rapid bronchoconstriction that peaked at 3–5 min and gradually resolved to within 30% of baseline V<sub>p30</sub> and 6% of baseline FEV₁ at 60 min (fig. 2a and b). There were no significant differences in the maximum falls of FEV₁ achieved after bradykinin and methacholine, their falls being 28 and 24%, respectively, (fig. 2a). Analyses of V<sub>p30</sub> data showed a significant difference in the maximum falls induced by bradykinin and methacholine challenge, their falls being 77 and 67%, respectively, (p=0.043) (fig. 2b). With both agonists, there were no significant correlations between either the maximum percentage fall in FEV₁ and baseline histamine PC<sub>20</sub>FEV₁ or the maximum percent fall in V<sub>p30</sub> and baseline PC<sub>40</sub>V<sub>p30</sub>. Bradykinin inhalation did not cause any late falls in FEV₁ or V<sub>p30</sub> (figs. 2a and b). The three subjects with moderately hyperresponsive airways (subjects Nos 1, 6 and 8) exhibited no difference in their responses to bradykinin when compared to the other six subjects, nor was there any significant difference between the bronchoconstrictor responses of the steroid and nonsteroid users.
Effect of bradykinin on histamine responsiveness

No significant difference was observed between the airways responsiveness to histamine after bradykinin exposure or methacholine control challenge when expressed in terms of PC_{20}FEV_{i} at any time-point postchallenge (fig. 3a). However, when airways responsiveness was monitored as PC_{20}V_{p30}, there were significant increases in histamine reactivity after bradykinin at 3 and 7 h when compared to the response after methacholine (placebo) (fig. 3b). The geometric mean PC_{20}V_{p30} histamine values after bradykinin challenge decreasing from 1.06 to 0.33 mg·ml^{-1} at 3 h (p<0.01), and from 0.96 to 0.45 mg·ml^{-1} at 7 h (p<0.05). The three subjects on regular inhaled corticosteroids (Subjects Nos 6, 8 and 9) exhibited no difference in their airway responsiveness to histamine after bradykinin when compared to the other six subjects. No correlation could be established between the magnitude of bradykinin-induced bronchoconstriction and the bradykinin-induced change in histamine responsiveness.

Discussion

In this study, we have confirmed that inhaled bradykinin is a potent bronchoconstrictor with a rapid onset and brief duration of action in asthmatic subjects [14, 15]. In addition, no late response was observed. We have also shown that, in contrast to methacholine, inhalation of bradykinin caused a transient increase in bronchial responsiveness to histamine when expressed as PC_{20}V_{p30} but not as PC_{20}FEV_{i}.

Since the use of flow rates from PEFV curves is said to better detect changes in the calibre of small rather than large airways [22], our findings suggest that bradykinin provokes a selective increase in peripheral airway responsiveness. Apart from being a very sensitive index of measuring the response to both bronchoconstrictor and bronchodilator agents [23, 24], flow rate values obtained from PEFV manoeuvres have the considerable advantage of not being affected by the possible artifacts associated with the deep inspiration which precede the maximal expiration for the recording of FEV_{i} (i.e. reflex bronchodilatation). The value of the observations on pharmacologically-induced changes in PC_{20}V_{p30} to inhaled histamine depends on the reproducibility of this response. V_{p30} readings are highly repeatable with the technique used, because the calculated coefficient of variations ranged 5–13%, which is in accordance with previously reported reproducibility limits [21, 24].

Although in asthmatic airways the bronchoconstrictor effect of bradykinin is likely to be mediated via a B_{2} receptor, as the B_{2} selective agonist [desArg^{9}]-bradykinin has no effect on airway function in asthmatic subjects [15], the precise mechanism by which kinins mediate bronchoconstriction in asthmatic subjects remains unclear. The mode of action of bradykinin in provoking bronchoconstriction in asthmatic subjects does not seem to involve the release of functionally active histamine [25], and the inhibition of cyclo-oxygenase by flurbiprofen or aspirin has little or no effect on the bronchoconstrictor response to bradykinin [14, 25]. The potent anticholinergic agent, ipratropium bromide, produces an approximately five fold protection for the airways against bronchoconstriction provoked by bradykinin [14], indicating that cholinergic vagal reflexes may, in part, contribute to this response.

The present study is the first to report the airway effects of bradykinin on bronchial responsiveness in man. Bradykinin has been reported to contribute to the increase in bronchial reactivity that follows allergen challenge in sheep [19]. This effect is not related to changes either in airway smooth muscle or in muscarinic and histamine (H_{1}) receptor density or function, and is probably the consequence of the ability of a selective bradykinin antagonist to reduce pulmonary inflammation [26]. In contrast to these published studies, when data of the proximal
airways ($FEV_1$) were included in the analysis, we failed to find any significant difference between changes in histamine responsiveness after inhaled bradykinin when compared with a similar initial bronchoconstrictor response provided by methacholine. The reason for this discrepancy is not clear. A precedent of this variable response has been reported in allergen-induced hyperresponsiveness that usually occurs in those who develop a late asthmatic response [7]. However, bradykinin did not produce a late response in any of our volunteers and it is consistent with the lack of subsequent increase in bronchial reactivity. The dose of bradykinin used in the present study might have been too low to elicit a detectable change in the $PC_{20}FEV_1$ histamine, but we cannot exclude the possibility that a higher dose or chronic exposure to this kinin could have been followed by a significant change in reactivity. To what extent the dose of bradykinin used might have affected our results is difficult to assess. However, consecutive challenges with bradykinin in asthmatic subjects failed to alter their airway responsiveness to histamine expressed as $PC_{20}FEV_1$ [27]. The subjects studied in the present investigation were a heterogeneous group of atopic and nonatopic asthmatics, with a wide range in baseline bronchial responsiveness to histamine and in their use of inhaled corticosteroids. Comparison between subjects showed no difference in their airway responses to histamine after bradykinin exposure; thus, indicating that it is unlikely that the lack of bradykinin-induced changes in airway reactivity can be accounted for by differences in subjects characteristics.

However, when the effect of bradykinin on baseline airway reactivity was expressed as $PC_{40}VP_{30}$ histamine, a statistically significant increase in responsiveness was observed at 3 and 7 h postchallenge, thereby suggesting that the change in airway responsiveness after bradykinin exposure is peculiar to peripheral airways. All our subjects demonstrated a 40% fall in $VP_{30}$ on all challenges to histamine and, therefore, the index of $PC_{40}VP_{30}$ acts as a reliable and sensitive index of bronchial responsiveness [21, 28]. The change in histamine responsiveness was observed but small and consistent. This small change would be unlikely to result in significant clinical symptoms, but the importance of this observation lies in the possible mechanism(s) of the increase in relation to the pathogenesis of airway hyperresponsiveness in asthma. It is unclear why the effect of bradykinin on histamine responsiveness was present only when $PC_{40}VP_{30}$ was used as an index of bronchial responsiveness. Although it cannot be excluded that this phenomenon might result from an artifact of the measurement, we believe that this is unlikely, since a similar change in $PC_{20}VP_{30}$ was not observed on the control study day with methacholine.

Bradykinin exposure may influence airway responses to histamine via three possible mechanisms. Firstly, it is possible that the change in responsiveness after bradykinin exposure is peculiar to peripheral airways due to regional difference in sensitivity [29]. Secondly, increased bronchial vascular permeability may lead to airway oedema and subsequent swelling of the airway walls, and may, therefore, affect baseline airway reactivity. In dogs, bradykinin is more potent than methacholine in inducing vasodilation and increase in the thickness of the airway mucosa [13], which is more significant in those parts of the airways where the ratio of change in mucosal thickness to the radius of adjacent lumen is large, such as in small conducting airways. A theoretical analysis suggests that a small increase in baseline airway calibre (i.e. due to mucosal thickening) might be expected to contribute to enhanced airway responsiveness for a given bronchoconstrictor stimulus, without any detectable change in resting lung function [30]. Using an elegant model that incorporates well-established fluid dynamic principles and detailed anatomical measurements of the airways, Wiggs et al. [31] demonstrated that smooth muscle constriction alone produces only relatively modest increases in small airway resistance, whereas, when the same degree of constriction was coupled with airway wall thickening, dramatic increases in resistance were recorded. Thirdly, another speculative possibility that could explain the increase in airway responsiveness following bradykinin exposure is sensitization of sensory nerve endings to histamine. Bradykinin is known to directly stimulate airway C-fibres [16, 18]. In guinea-pigs, a combination of atropine and capsaicin pretreatment largely abolishes the bronchoconstrictor response to instilled bradykinin, indicating that both a cholinergic reflex and release of neuropeptides from sensory nerves play a part [32]. Although sensory nerves sensitization is not known to occur in vivo, a recent study by Djukanovic et al. [33] has shown that inhaled allergen causes an upregulation of neuroeffector mechanisms in atopic asthmatics, reflected by a decrease in threshold for bradykinin stimulation. However, this does not explain the disparity in the response observed in this study with different indicators of bronchial reactivity.

In conclusion, our study showed that bradykinin exposure causes prompt bronchoconstriction, which was not followed by any significant late fall. When measured by the $PC_{20}FEV_1$, histamine, we were unable to demonstrate induction of airway hyperresponsiveness by bradykinin in this group of asthmatic volunteers. However, when the more sensitive index $PC_{20}VP_{30}$, histamine was used as a marker of bronchial responsiveness, a significant increase in airway reactivity was detected up to 7 h, thus implicating bradykinin in the pathogenesis of airway hyperresponsiveness. This observation is of importance, because it provides a rational basis for the validation and the safe implementation of dose-response studies with inhaled bradykinin after pharmacological testing. However, none of the studies in humans have yet addressed the effects of bradykinin inhalation over prolonged periods, which for ethical reasons would be difficult to undertake, but is clearly a more relevant model of ongoing bradykinin formation in the inflamed airways of asthma. A more definitive understanding of the potential role of this mediator in the pathogenesis of airway hyperresponsiveness and asthma will only be possible once selective bradykinin receptor antagonists are made available for use in humans.
References


